Table 4.

Risk of a pituitary tumor in relation to hormonal contraceptive use and treatment, evaluated up to the date of interview in a case-control study, United Kingdom, 2001 to 2005

FactorCases (n = 157)
Controls (n = 336)
OR (95% CI)*P
n%n%
Oral contraceptive use
    Ever
        No3522.35315.81.0
        Yes12277.728384.20.8 (0.4-1.4)0.38
    Duration of oral contraceptive use (y)
        <1159.6257.41.6 (0.7-4.1)0.30
        1-43622.98224.40.8 (0.4-1.7)0.64
        5-92817.88425.00.5 (0.2-1.1)0.07
        ≥104226.89026.80.7 (0.4-1.5)0.41
        Not known10.620.6Trend (all subjects) P = 0.2
Trend (ever users only) P = 0.3
HRT
    Ever
        No11673.923469.61.00.16
        Yes4126.110230.41.5 (0.8-2.6)
    Duration of HRT use (y)
        <1138.3175.13.3 (1.3-8.6)0.01
        1-4138.3288.31.5 (0.6-3.3)0.37
        5-995.73711.00.9 (0.4-2.3)0.85
        ≥1063.8206.01.1 (0.4-3.4)0.87
        Not knownTrend (all subjects) P = 0.6
Trend (ever use only) P = 0.4
  • * ORs obtained from unconditional logistic regression model adjusted for age at reference date, region, interview year, and Townsend deprivation score.